OKYO Pharma director buys 5,000 shares on Nasdaq

OKYO Pharma Limited reports that Non-Executive Director John Brancaccio purchased 5,000 of its ordinary shares on Nasdaq at $1.48 per share, increasing his holding to 35,201 shares.

Rhea-AI Filing Summary

OKYO Pharma Limited reports that Non-Executive Director John Brancaccio purchased 5,000 of its ordinary shares on Nasdaq at $1.48 per share, increasing his holding to 35,201 shares. The information is furnished and incorporated by reference into an existing Form F-3 registration statement.

The company describes itself as a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. It plans a global Phase 3 pivotal clinical trial of urcosimod for NCP in the second half of this year, enrolling approximately 111 patients on a single-dose regimen.

Key Figures

Director share purchase: 5,000 shares Purchase price: $1.48 per share Director total holdings: 35,201 shares +1 more

4 metrics

Director share purchase 5,000 shares Ordinary shares bought on Nasdaq by Non-Executive Director John Brancaccio

Purchase price $1.48 per share Price paid for the 5,000 ordinary shares

Director total holdings 35,201 shares Total ordinary shares held by John Brancaccio after the purchase

Phase 3 trial enrollment approximately 111 patients Planned enrollment for global Phase 3 pivotal urcosimod trial in neuropathic corneal pain

Key Terms

neuropathic corneal pain (NCP), anterior segment eye diseases, clinical-stage biopharmaceutical company, Phase 3 pivotal clinical trial, +2 more

6 terms

neuropathic corneal pain (NCP) medical

"developing investigational therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic eye pain caused by damage or abnormal signaling in the nerves of the cornea, producing burning, stinging, or painful sensitivity often without visible surface injury. It matters to investors because it creates demand for specialized diagnostics and long‑term treatments distinct from standard eye drops—think of it like phantom limb pain for the eye—making it a potential market for new therapies and medical devices.

anterior segment eye diseases medical

"developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases"

Diseases of the anterior segment of the eye are medical conditions that affect the front part of the eye—including the cornea, iris, lens, and the front chamber—similar to damage or fogging on a car’s windshield that interferes with vision. They matter to investors because this category drives demand for drugs, surgical devices, diagnostic tools, and clinical trials; prevalence, regulatory approvals, and reimbursement decisions can directly affect companies’ revenues and valuations.

clinical-stage biopharmaceutical company medical

"OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies"

A clinical-stage biopharmaceutical company develops drugs or medical therapies that are being tested in people in formal clinical trials but do not yet have any approved, marketed products. For investors, these firms behave like prototype makers: their value depends heavily on trial results and regulatory decisions, so they can swing widely on a single study, consume cash while testing, and offer either large upside if trials succeed or big downside if they fail.

Phase 3 pivotal clinical trial medical

"OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year"

A phase 3 pivotal clinical trial is the late-stage, large-scale human study designed to confirm a medical treatment’s safety and effectiveness and provide the main evidence regulators use to decide on approval. For investors it’s a make-or-break test: a successful result is like a final dress rehearsal that clears the way for product launch and future sales, while failure can halt development and erase expected value.

single-dose regimen medical

"enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP"

A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.

urcosimod medical

"evaluate a single-dose regimen of urcosimod for the treatment of NCP"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What director share purchase did OKYO (OKYO) report in this 6-K?

OKYO Pharma reported that Non-Executive Director John Brancaccio bought 5,000 ordinary shares on Nasdaq at $1.48 per share. This transaction increases his total holding to 35,201 shares, reflecting a modest increase in his personal stake in the company.

At what price and on which market did OKYO (OKYO) shares get purchased by the director?

The shares were purchased on the Nasdaq at a price of $1.48 per share. The transaction involved 5,000 ordinary shares of OKYO Pharma and was disclosed as part of the company’s regular foreign issuer reporting obligations.

What is Non-Executive Director John Brancaccio’s total shareholding in OKYO (OKYO) after the purchase?

After the reported purchase, John Brancaccio holds 35,201 ordinary shares of OKYO Pharma. This total reflects the addition of 5,000 shares acquired in the latest transaction disclosed in the company’s July 2026 foreign issuer report.

What therapies is OKYO (OKYO) currently developing?

OKYO Pharma is developing investigational therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. It describes itself as a clinical-stage biopharmaceutical company, with its ordinary shares listed for trading on the Nasdaq Capital Market.

What key clinical trial does OKYO (OKYO) plan to start and when?

OKYO plans to initiate a global Phase 3 pivotal clinical trial of urcosimod for neuropathic corneal pain in the second half of this year. The study is expected to enroll approximately 111 patients using a single-dose regimen.

How is this OKYO (OKYO) disclosure linked to its existing registration statement?

The information about the director’s share purchase is incorporated by reference into OKYO Pharma’s existing Form F-3 registration statement. The company specifies that the news announcement is furnished, not deemed filed, under U.S. securities law provisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 12:00 PM Accepted by SEC EDGAR 07/23/2026 - 12:00 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On July 23, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing that OKYO Pharma’s Non-Executive Director, John Brancaccio has purchased 5,000 of the Company’s ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to 35,201 shares.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: July 23, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated July 23, 2026

4

Exhibit 99.1

OKYO Pharma Announces Purchase of Shares by Director

London and New York, NY, July 23, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Non-Executive Director, John Brancaccio has purchased 5,000 of the Company’s ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to 35,201 shares.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd

Paul Spencer

Business Development and Investor Relations

+44 (0) 207 495 2379

Email: info@okyopharma.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 5.6 KB
• EX-99 GRAPHIC 18.9 KB